Cerebral Sinus Thrombosis in a Trauma Patient after Recombinant Activated Factor VII Infusion

Universität Mannheim, Mannheim, Baden-Württemberg, Germany
Anesthesiology (Impact Factor: 5.88). 03/2004; 100(2):441-3. DOI: 10.1097/00000542-200402000-00037
Source: PubMed
8 Reads
  • Source
    • "In our study, this was reflected in that no patient treated with rFVIIa suffered any form of thromboembolic complications or adverse events. There are few reports on complications reported in literature though.[20] Since none of our patients evaluated had hemophilia or had risk factors for thromboembolic complications, safety of rFVIIa in our study needs further validation. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Factor VIIa (recombinant) has an off-label use to control life-threatening bleeding that is refractory to other measures and was shown to decrease transfusion requirements. The primary objective of this study was to assess the safety and effectiveness of factor VIIa (recombinant) on blood transfusion requirements and coagulation parameters when used in patients whose bleeding was uncorrected by other means. The pharmacoeconomic impact for any discrepancy from our protocol was evaluated. Secondary outcomes included 4-hour and 28-day mortality, as well as safety of this agent in terms of thromboembolic complications. We retrospectively evaluated patients who received recombinant-activated factor VII (rFVIIa) for uncontrolled bleeding from June 2008 to April 2011. The medical records of 33 patients were evaluated. Coagulation parameters and blood products were determined 24 hours before and 24 hours after administration of rFVIIa, and the results compared. Patients were also screened for any thromboembolic complications. Administration of rFVIIa reduced blood transfusion requirements and improved coagulation parameters significantly (P<0.05). No thromboembolic complications were reported. Most of the dosing was consistent with those recommended in our institutional protocol, with discrepancies resulting in an average cost of $56 058. Moreover, pH was reported in only 67% of patients. All patients treated with rFVIIa survived up to 4 hours after receiving this agent, while the 28-day mortality was 24% (8/33). The use of rFVIIa appears to be safe and effective in promoting hemostasis, as evident from reducing transfusion requirements and improving the coagulation variables.
    Full-text · Article · Mar 2012 · Asian Journal of Transfusion Science
  • Source
    • "Siegel and colleagues [32] reported on a 19-year-old polytrauma patient suffering from an open shaft fracture of the femur, pneumothorax, lung contusion, and a mild TBI (GCS = 15) with no intracranial pathology on initial CT. The patient was treated with 60 μg/kg rFVIIa to control bleeding from his thigh 12 hours after orthopedic surgery for stabilizing his fracture. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Trauma is a leading cause of mortality and morbidity, with traumatic brain injury (TBI) and uncontrolled hemorrhage responsible for the majority of these deaths. Recombinant activated factor VIIa (rFVIIa) is being investigated as an adjunctive hemostatic treatment for bleeding refractory to conventional replacement therapy in trauma patients. TBI is a common component of polytrauma injuries. However, the combination of TBI with polytrauma injuries is associated with specific risk factors and treatment modalities somewhat different from those of polytrauma without TBI. Although rFVIIa treatment may offer added potential benefit for patients with combined TBI and polytrauma, its safety in this population has not yet been assessed. We conducted a post hoc sub analysis of patients with TBI and severe blunt polytrauma enrolled into a prospective, international, double-blind, randomized, placebo-controlled study. A post hoc analysis of study data was performed for 143 patients with severe blunt trauma enrolled in a prospective, randomized, placebo-controlled study, evaluating the safety and efficacy of intravenous rFVIIa (200 + 100 + 100 microg/kg) or placebo, to identify patients with a computed tomography (CT) diagnosis of TBI. The incidences of ventilator-free days, intensive care unit-free days, and thromboembolic, serious, and adverse events within the 30-day study period were assessed in this cohort. Thirty polytrauma patients (placebo, n = 13; rFVIIa, n = 17) were identified as having TBI on CT. No significant differences in rates of mortality (placebo, n = 6, 46%, 90% confidence interval (CI): 22% to 71%; rFVIIa, n = 5, 29%, 90% CI: 12% to 56%; P = 0.19), in median numbers of intensive care unit-free days (placebo = 0, rFVIIa = 3; P = 0.26) or ventilator-free days (placebo = 0, rFVIIa = 10; P = 0.19), or in rates of thromboembolic adverse events (placebo, 15%, 90% CI: 3% to 51%; rFVIIa, 0%, 90% CI: 0% to 53%; P = 0.18) or serious adverse events (placebo, 92%, 90% CI: 68% to 98%; rFVIIa, 82%, 90% CI: 60% to 92%; P = 0.61) were observed between treatment groups. The use of a total dose of 400 (200 + 100 + 100) microg/kg rFVIIa in this group of hemodynamically unstable polytrauma patients with TBI was not associated with an increased risk of mortality or with thromboembolic or adverse events.
    Full-text · Article · Feb 2007 · Critical care (London, England)
  • Source
    • "However, rFVIIa-treated patients had a higher mortality than did the coagulopathic controls [6]. By broadening the indications and using an early or preventive strategy, the potential complications of disseminated intravascular coagulation (DIC) and thrombotic events [12] [13], such as myocardial infarction (MI), cerebrovascular thrombosis, and venous thrombosis, become a concern. In this article, we describe three patients with severe TBI who were treated with rFVIIa. "
    [Show abstract] [Hide abstract]
    ABSTRACT: We report three patients with severe traumatic brain injury, both open and closed, who were treated with recombinant activated factor VII. This treatment was given in a desperate, last-ditch effort to save the life of patient 1, as a preventive or early treatment of a developing hematoma in patient 2, and as treatment of a threatening hematoma in patient 3. One of the three patients survived. During the past few years we have broadened the indications for recombinant activated factor VII and started using it as a preventive measure rather than as a "last line of defense." However, the potential complications of disseminated intravascular coagulation and thrombotic events, as well as the cost-effectiveness in view of the available evidence-based medicine, should be considered.
    Full-text · Article · Dec 2006 · Journal of Clinical Anesthesia
Show more